TenQ · fact sheet · filings current to · price as of
Eli Lilly (LLY)
A mixed picture - strengths and real weaknesses - 22 of 28 checks passed.
Latest close : $1149.36, -0.9% on the day; -10.2% from the 52-week high. Refreshed every trading night.
Full analysis: report · all charts. Financial statements are computed from SEC EDGAR XBRL filings, current to . The share price and everything built on it (market cap, multiples, yields, the Value and Trend checks) are refreshed every trading night; this page shows the close of . Not investment advice.
Key figures
| Share price (delayed close) | $1149.36 |
| Market cap | $1.08T |
| 52-week range | $710.11 - $1280.34 |
| P/E | 38.7x |
| P/E, own 10-year median | 35.0x |
| P/S | 13.6x |
| Free cash flow yield | - |
| Dividend yield | 0.5% |
| Revenue (TTM) | $79.7B |
| Net income (TTM) | $26.7B |
| Free cash flow (TTM) | - |
| Gross margin | 83.4% |
| Operating margin | - |
| Return on equity | 78.8% |
| Revenue growth (1y) | +49.6% |
| Revenue CAGR (3y) | +31.7% |
| Debt / equity | 1.62x |
| Cash & short-term investments | $9.1B |
| Shares outstanding | 941.4m (cover page of the latest filing, 2026-08-03) |
The score: 22 of 28 checks passed
Six chapters, six pass/fail checks each. Five are computed from the filings; Trend is price behaviour, and says so.
Is LLY stock cheap or expensive right now?
Value · not scored. Not enough data to score this fairly - the checks below show exactly what's missing. (EBITDA at or below zero, or unavailable; free cash flow or market cap unavailable; under 3 years of cash-flow history) chapter →
Is Eli Lilly still growing?
Growth · 6 of 6 checks passed. The business is genuinely growing - revenue +49.6% in the last year, and it's consistent. chapter →
Does Eli Lilly make real money?
Quality · 4 of 4 checks passed. A solidly profitable business, though not exceptional against its sector. chapter →
Can Eli Lilly survive a bad year?
Health · 2 of 4 checks passed. The balance sheet carries real risk - read the checks before anything else. chapter →
What does Eli Lilly hand back to shareholders?
Shareholder returns · 4 of 5 checks passed. Cash comes back to owners, with a caveat or two in the checks below. chapter →
Which way is LLY trending?
Trend analysis · 5 of 6 checks passed. The market agrees: the stock is in a healthy uptrend on every horizon. chapter →
Are insiders buying or selling LLY?
Open-market buys: $0.00 · sells: $35M, across the recent Form 4 filings. detail →
Other pharma and chemicals we cover: Johnson & Johnson (JNJ) · Pfizer (PFE) · every company →
Method: figures computed deterministically from SEC EDGAR XBRL (companyfacts, frames, financial-statement-and-notes datasets, Form 4); prices delayed end-of-day. Scores count transparent pass/fail checks. Missing data is shown as missing, never estimated. Last changed . © TenQ - cite with a link to this page.